CR 001 - Crescent Biopharma
Alternative Names: CR-001 - Crescent BiopharmaLatest Information Update: 03 Dec 2024
Price :
$50 *
At a glance
- Originator Crescent Biopharma; Paragon Therapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Programmed cell death-1 ligand-1 modulators; Vascular endothelial growth factors modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours